Ritu Baral
Stock Analyst at TD Cowen
(1.21)
# 3,585
Out of 4,947 analysts
31
Total ratings
37.04%
Success rate
-4.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $49.38 | +53.91% | 1 | Aug 4, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $47.30 | -6.98% | 1 | Feb 5, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $1.91 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.07 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $46.47 | +67.85% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $448.91 | -17.36% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $127.80 | -23.32% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $369.84 | +5.45% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $7.67 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $21.81 | +702.38% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $25.33 | -17.09% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.60 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.79 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.88 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.54 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.05 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.55 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.51 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $754.24 | - | 2 | Jan 12, 2018 |
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $49.38
Upside: +53.91%
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $47.30
Upside: -6.98%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.91
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.07
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $46.47
Upside: +67.85%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $448.91
Upside: -17.36%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $127.80
Upside: -23.32%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $369.84
Upside: +5.45%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.67
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $21.81
Upside: +702.38%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $25.33
Upside: -17.09%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.60
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.79
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.88
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.54
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.05
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.51
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $754.24
Upside: -